Related Experiment Video
Updated: Sep 18, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Prognostic value of CMR-derived extracellular volume in myocardial infarction with non-obstructive coronary arteries
Lei Chen1, Liqi Ge2, Fuad A Abdu1
1Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Background:
Cardiac magnetic resonance (CMR) is crucial for diagnosing myocardial infarction with non-obstructive coronary arteries (MINOCA) and is recommended by current guidelines for its diagnostic and prognostic capabilities. However, the prognostic value of CMR parameters, particularly extracellular volume (ECV), in predicting major adverse cardiovascular events (MACE) among MINOCA remains unclear. This study analyzes ECV distribution across different MINOCA etiologies and its predictive value for MACE in "true" MINOCA.
Methods:
Consecutive patients with a working diagnosis of MINOCA who underwent CMR were included. We investigated the relationships between CMR parameters and MACE in "true" MINOCA. Cox regression and ROC curve analyses were used to assess ECV in predicting MACE. "True" MINOCA was defined by evidence of ischemia or infarction on CMR.
Results:
Among 275 patients with a working diagnosis of MINOCA (median 4 days to CMR), 96 were diagnosed with "true" MINOCA, 66 with myocarditis, 31 with Takotsubo syndrome (TS), 34 with cardiomyopathies, and 48 had normal findings. "True" MINOCA had higher ECV compared to other etiologies (29.10 % vs. 26.00 %, P < 0.001). During a median follow-up of 26.6 months, 29.2 % of "true" MINOCA patients experienced MACE. In the adjusted Cox model, ECV (HR 1.063, 95 % CI 1.019-1.108, P = 0.004) was an independent predictor of MACE in patients with "true" MINOCA. According to optimal cut-off values from ROC, patients with ECV >28.94 % had a significantly higher MACE risk (log-rank P < 0.001).
Conclusions:
CMR-derived ECV varies by MINOCA etiology, with higher levels in "true" MINOCA. Elevated ECV independently predicts increased MACE risk in "true" MINOCA patients.
Trial Registration Number:
ClinicalTrials.gov (ID: NCT06502899).
More Related Videos
06:29Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019
11:13Quantification of Mouse Heart Left Ventricular Function, Myocardial Strain, and Hemodynamic Forces by Cardiovascular Magnetic Resonance Imaging
Published on: May 24, 2021
Related Concept Videos
Imaging Studies for Cardiovascular System IV: CMRI
Cardiomyopathy IV: Restrictive Cardiomyopathy
Acute Coronary Syndrome III: Diagnostic Studies
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Stenosis II: Clinical features and Diagnostic Tests